<DOC>
	<DOCNO>NCT02792179</DOCNO>
	<brief_summary>This longitudinal , follow-up study participant Alzheimer 's disease ( AD ) previously participate study BP29409 ( NCT02187627 ) . This study design assess longitudinal change Tau pathology brain participant AD use PET ligand [ 18F ] RO6958948 ass safety tolerability PET ligand .</brief_summary>
	<brief_title>Evaluation 18FRO6958948 Tracer Positron Emission Tomography ( PET ) Imaging Tau Burden Alzheimer 's Disease Participants</brief_title>
	<detailed_description />
	<mesh_term>Alzheimer Disease</mesh_term>
	<criteria>AD participant previously scan [ 18F ] RO6958948 Roche Study BP29409 Agreement use highly effective contraception measure Body mass index ( BMI ) 18 32 Kilograms per square meter ( kg/m^2 ) A study partner able accompany participant visit answer question participant In opinion investigator , base medical history physical examination , safely tolerate tracer administration scan procedure Documented positive visual read ( per local procedure florbetapir similar procedure amyloid tracer ) amyloid PET scan , opinion principal investigator consistent diagnosis AD Exclusion Criteria All Participants History presence clinically relevant hematological , hepatic , respiratory , cardiovascular , renal , metabolic , endocrine , central nervous system disease medical condition well control , may put participant risk , could interfere objective study , make participant unsuitable participation study reason opinion principal investigator Clinically relevant pathological finding physical examination , electrocardiogram , laboratory value screen assessment could impact participant safety Known history clinically significant infectious disease include autoimmune deficiency syndrome ( AIDS ) serological indication acute/chronic hepatitis B C Human Immuno Virus infection Women childbearing potential must pregnant , nurse serum human chorionic gonadotropin ( HCG ) must negative time Screening Visit 1 , urine HCG must negative subsequent visit Loss donation 450 milliliter ( mL ) blood 4 month screen donation plasma within 14 day screen Unsuitable vein repeat venipuncture History drug alcohol abuse positive result urine screen drug abuse Have receive investigational medication within last 3 month 5 time elimination halflife , whichever longer , prior enrollment Exclusion Criteria Related Trial Procedures Has planning exposure ionize radiation combination studyrelated tracer administration scan procedure would result cumulative exposure exceed recommend annual exposure limit Presence pacemaker ; aneurysm clip ; artificial heart valve ; ear implant ; foreign metal object eye , skin , body , circumstance would contraindicate magnetic resonance imaging ( MRI ) scan History , suffers , claustrophobia feel unable lie still back MRI PET scanner Has receive treatment target amyloidbeta tau within last 24 month</criteria>
	<gender>All</gender>
	<minimum_age>25 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>